| Q34413330 | A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis |
| Q24806847 | Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis |
| Q24197936 | Bisphosphonates for osteoporosis in people with cystic fibrosis |
| Q24200401 | Bisphosphonates for osteoporosis in people with cystic fibrosis |
| Q24239980 | Bisphosphonates for osteoporosis in people with cystic fibrosis |
| Q37374661 | Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis |
| Q34540323 | Bisphosphonates in bone diseases other than osteoporosis. |
| Q24805600 | Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis |
| Q35551169 | Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Regis |
| Q35901092 | Clinical development of anti-RANKL therapy |
| Q37342578 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. |
| Q40903047 | Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments |
| Q46760074 | Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study |
| Q88160122 | Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison |
| Q46568825 | Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis |
| Q37989394 | Inflammatory bone loss: pathogenesis and therapeutic intervention |
| Q46679485 | Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models |
| Q24806684 | Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications |
| Q34637331 | Pathogenesis of bone lesions in rheumatoid arthritis |
| Q77575066 | Prevention and treatment of glucocorticoid-induced osteoporosis |
| Q42136336 | RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro |
| Q36568516 | Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways |
| Q74777716 | Rheumatoid arthritis in older adults |
| Q36559431 | Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis |
| Q35547936 | Should we look for osteoporosis in patients with rheumatoid arthritis? |
| Q35788463 | TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis |
| Q43601694 | The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone |
| Q37808268 | The crossover of bisphosphonates to cancer therapy |
| Q34071304 | The final pathogenetic steps in focal bone erosions in rheumatoid arthritis |
| Q81376464 | The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis |
| Q24797889 | The role of osteoprotegerin in arthritis |
| Q45249079 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin |
| Q35140855 | Therapeutic strategies for rheumatoid arthritis |
| Q74103229 | [Inflammation and bone metabolism in rheumatoid arthritis. Pathogenetic viewpoints and therapeutic possibilities] |
| Q73164408 | [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis] |